Heat Biologics Inc (HTBX) 1.34 $HTBX
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
PR Newswire - Mon Aug 29, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services ("KCAS" and Heat Biologics, Inc. ("Heat" .
HTBX: 1.34 (-0.02), CYRX: 2.06 (+0.01)
Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
-- Poster reviews trial design and endpoints
HTBX: 1.34 (-0.02)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.34 (-0.02), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.25 (-0.12)
Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.
GlobeNewswire - Tue Apr 26, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at PIONEERS 2016, presented by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:00 p.m. Eastern Time.
HTBX: 1.34 (-0.02)
Heat Biologics Appoints Dr. John Prendergast to Board of Directors
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company has appointed John Prendergast, Ph.D., to its Board of Directors, effective April 21, 2016. Dr. Prendergast will replace Paul Belsky, M.D., who has served on Heat's board since 2009.
HTBX: 1.34 (-0.02)
Heat Biologics and OncoSec Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 5:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that preclinical data from its collaboration with OncoSec Medical Incorporated ("OncoSec" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 1.34 (-0.02)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec" (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).
HTBX: 1.34 (-0.02), ONCS: 1.71 (unch)
Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity
ACCESSWIRE - Fri Apr 15, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Cancer news seen on all types of media - television, radio, print, webinars, investor and scientific meetings, and grass root blogs, is covered for a reason. Up to 40% of people in the US alone develop cancer, according the National Cancer Institute. Breast cancer and leukemia get the lion's share of attention, but other cancers are just as dangerous. I believe Heat Biologics (NasdaqCM: HTBX), one of the most forward-thinking and innovative companies in cancer immunotherapy geared toward cures for non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), will be a winner in the race to bring medicine a giant step forward.
HTBX: 1.34 (-0.02), MRK: 62.91 (+0.01), SNY: 39.13 (+0.72)
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 12, 5:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced three poster presentations at the AACR Annual Meeting, including initial preclinical results from Heat's collaboration with OncoSec Medical Incorporated, a biotechnology company developing DNA-based intra-tumoral cancer immunotherapies. The AACR Annual Meeting is being held on April 16-20, 2016 in New Orleans, LA.
HTBX: 1.34 (-0.02)
Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones
GlobeNewswire - Thu Apr 07, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is implementing cost-saving measures and a focused corporate strategy to achieve, with its current cash on-hand, data readout in the fourth quarter of 2016 for its lead Phase 2 program evaluating HS-410 for the treatment of non-muscle invasive bladder cancer. These cost-saving measures include a workforce reduction of approximately 22% of the company's headcount and a reduction in compensation for the remaining leadership team. Heat also announced the voluntary resignation of two members from its Board of Directors. In addition, Heat will further decrease operating expenses by advancing only the eight patients currently enrolled in its Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer instead of enrolling the eighteen patients initially planned. Heat intends to focus its resources to achieve the important near-term milestones for these two product candidates, both of which are expecting topline data in the fourth quarter of 2016.
HTBX: 1.34 (-0.02)
Heat Biologics to Participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 6 Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled "Therapeutic Cancer Vaccines: Stimulating the Immune System," as well as a second panel discussion starting at 4:30 p.m. ET entitled "Combination Immuno-Oncology Themes."
HTBX: 1.34 (-0.02)
FDA Lifts Heat Biologics Partial Clinical Hold
GlobeNewswire - Wed Feb 10, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's Phase 2 clinical trial evaluating HS-410 either alone or in combination with standard of care Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat will resume patient enrollment.
HTBX: 1.34 (-0.02)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 1.34 (-0.02), ARGS: 4.93 (-0.02), ENZ: 5.74 (-0.11), GILD: 77.59 (+0.17), GSK: 44.08 (+1.10), BMY: 55.94 (-0.82)
Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
GlobeNewswire - Tue Jan 26, 6:02AM CST
-- Early results support mechanism of action
HTBX: 1.34 (-0.02)
Heat Biologics to Present at Biotech Showcase 2016
GlobeNewswire - Thu Jan 07, 3:14PM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Jeff Wolf, Heat's Chief Executive Officer, will deliver a corporate presentation at the 8 Annual Biotech Showcase(TM), being held January 11-13, 2016 in San Francisco, CA.
HTBX: 1.34 (-0.02)
Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
M2 - Tue Dec 22, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/q3dfhj/global_cancer) has announced the addition of the "Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020" report to their offering. The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period. Key Topics Covered: 1. Executive Summary 2. Global - Cancer Vaccines Market and Forecast to 2020 3. Global - Cancer Vaccines Market Share and Forecast to 2020 4. Global - Prophylactic Cancer Vaccines Market and Forecast to 2020 5. Global - Therapeutics Cancer Vaccines Market and Forecast to 2020 6. Cancer Vaccines Market - Regional Analysis 7. Global Cancer Vaccines Market - Major Deals 8. Global Cancer Vaccines - Funding 9. Global Cancer Vaccines Market - Pipeline Portfolio Analysis 10. Company Cancer Vaccines - Pipeline Analysis 11. Global Cancer Vaccines Market - Driving Factors 12. Global Cancer Vaccines Market - Challenges Companies Mentioned: - Aduro Biotech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Celldex Therapeutics - CureVac - Galena Biopharma - Genexine - GlobeImmune - Gradalis - Heat Biologics - Immatics - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - ISA Pharmaceuticals - Juvaris Biotherapeutics - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Oncovir - Oxford BioMedica - Prima BioMed - Sotio - Transgene - Ubivac - Vaccinogen - Vaxon Biotech For more information visit http://www.researchandmarkets.com/research/q3...bal_cancer
HTBX: 1.34 (-0.02), INO: 9.18 (+0.04), ARGS: 4.93 (-0.02), NWBO: 0.34 (unch), ADRO: 14.15 (-0.07), CLDX: 3.33 (-0.03), NLNK: 10.39 (+0.08), GALE: 0.41 (+0.01), IMUC: 0.12 (-0.01)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015 - 15 Companies & 21 Drug Profiles
M2 - Mon Dec 07, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/s7bjp9/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - APIM Therapeutics AS - Astellas Pharma Inc. - Bavarian Nordic A/S - BioCancell Ltd - Celgene Corporation - Cold Genesys, Inc. - Heat Biologics, Inc. - Spectrum Pharmaceuticals, Inc. - TARIS BioMedical, Inc. - Telesta Therapeutics Inc. - Telormedix SA - Vakzine Projekt Management GmbH - Viralytics Ltd. - Viventia Biotechnologies Inc. Drug Profiles - ALT-801 - ALT-803 - apaziquone - APL-1202 - ATX-101 - BC-819 - Biologic for Superficial Bladder Cancer - CG-0070 - CV-301 - CVA-21 - DAB-389EGF - docetaxel - Drug for NMIBC - erlotinib hydrochloride - imiquimod - lenalidomide - mitomycin SR - Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - oportuzumab monatox - rAd-IFN - sirolimus albumin-bound - TD-210 - Urocidin - vesigenurtucel-L - VPM-1002 For more information visit http://www.researchandmarkets.com/research/s7bjp9/non_muscle
HTBX: 1.34 (-0.02), SPPI: 5.20 (-0.09), CELGZ: 1.13 (-0.03)
Heat Biologics Appoints Timothy Creech as Chief Financial Officer
GlobeNewswire - Tue Dec 01, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced the appointment of Timothy Creech as Heat's new Chief Financial Officer.
HTBX: 1.34 (-0.02)
Heat Biologics Selected as One of Informa's 2015 Top 10 Immuno-Oncology Companies to Watch
GlobeNewswire - Wed Nov 18, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, has been chosen by Informa as one of the 2015 Top 10 Immuno-Oncology Companies to Watch. Anil Goyal, Ph.D., Heat's Vice President of Business Development, will present at the 10 Annual Therapeutic Area Partnerships meeting on November 18-20, 2015 at the Hilton Back Bay in Boston. Dr. Goyal's presentation is scheduled on Thursday, November 19, 2015 at 1:15 p.m. Eastern Time.
HTBX: 1.34 (-0.02)
Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire - Fri Nov 06, 6:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced results from its Phase 1 trial to evaluate safety and immune response to HS-410 (vesigenurtacel-L), after standard of care Bacillus Calmette-Guerin (BCG), for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). HS-410 had a positive safety profile and was well-tolerated with no patients discontinuing the trial due to adverse events. Furthermore, no serious adverse events were reported, and 7 out of 10 patients had no documented recurrence of cancer >1 year after standard of care surgery. Significantly, 3 out of 4 patients with carcinoma in situ (CIS), the patient population least responsive to standard of care, did not recur.
HTBX: 1.34 (-0.02)
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
PR Newswire - Mon Aug 29, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"
, the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services ("KCAS" and Heat Biologics, Inc. ("Heat" . HTBX: 1.34 (-0.02), CYRX: 2.06 (+0.01)
Heat Biologics Presents a Poster on its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial at ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
-- Poster reviews trial design and endpoints
HTBX: 1.34 (-0.02)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.34 (-0.02), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.25 (-0.12)
Heat Biologics to Present at PIONEERS 2016, Presented by Joseph Gunnar & Co.
GlobeNewswire - Tue Apr 26, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at PIONEERS 2016, presented by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:00 p.m. Eastern Time. HTBX: 1.34 (-0.02)
Heat Biologics Appoints Dr. John Prendergast to Board of Directors
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company has appointed John Prendergast, Ph.D., to its Board of Directors, effective April 21, 2016. Dr. Prendergast will replace Paul Belsky, M.D., who has served on Heat's board since 2009. HTBX: 1.34 (-0.02)
Heat Biologics and OncoSec Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Mon Apr 18, 5:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that preclinical data from its collaboration with OncoSec Medical Incorporated ("OncoSec" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org). HTBX: 1.34 (-0.02)
OncoSec and Heat Biologics Present Data at the American Conference for Cancer Research (AACR) Annual Meeting
PR Newswire - Mon Apr 18, 5:00AM CDT
OncoSec Medical Incorporated ("OncoSec"
(NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that preclinical data from its collaboration with Heat Biologics, Inc. ("Heat" focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org). HTBX: 1.34 (-0.02), ONCS: 1.71 (unch)
Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity
ACCESSWIRE - Fri Apr 15, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Cancer news seen on all types of media - television, radio, print, webinars, investor and scientific meetings, and grass root blogs, is covered for a reason. Up to 40% of people in the US alone develop cancer, according the National Cancer Institute. Breast cancer and leukemia get the lion's share of attention, but other cancers are just as dangerous. I believe Heat Biologics (NasdaqCM: HTBX), one of the most forward-thinking and innovative companies in cancer immunotherapy geared toward cures for non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), will be a winner in the race to bring medicine a giant step forward.
HTBX: 1.34 (-0.02), MRK: 62.91 (+0.01), SNY: 39.13 (+0.72)
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 12, 5:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced three poster presentations at the AACR Annual Meeting, including initial preclinical results from Heat's collaboration with OncoSec Medical Incorporated, a biotechnology company developing DNA-based intra-tumoral cancer immunotherapies. The AACR Annual Meeting is being held on April 16-20, 2016 in New Orleans, LA. HTBX: 1.34 (-0.02)
Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestones
GlobeNewswire - Thu Apr 07, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is implementing cost-saving measures and a focused corporate strategy to achieve, with its current cash on-hand, data readout in the fourth quarter of 2016 for its lead Phase 2 program evaluating HS-410 for the treatment of non-muscle invasive bladder cancer. These cost-saving measures include a workforce reduction of approximately 22% of the company's headcount and a reduction in compensation for the remaining leadership team. Heat also announced the voluntary resignation of two members from its Board of Directors. In addition, Heat will further decrease operating expenses by advancing only the eight patients currently enrolled in its Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer instead of enrolling the eighteen patients initially planned. Heat intends to focus its resources to achieve the important near-term milestones for these two product candidates, both of which are expecting topline data in the fourth quarter of 2016. HTBX: 1.34 (-0.02)
Heat Biologics to Participate in the 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer, will participate in the 6 Annual Cancer Immunotherapy: A Long-Awaited Reality Conference being held Thursday, March 31, 2016 at the Apella Event Space at Alexandria Center in New York City. Dr. Schreiber will join a panel discussion starting at 11:00 a.m. ET entitled "Therapeutic Cancer Vaccines: Stimulating the Immune System," as well as a second panel discussion starting at 4:30 p.m. ET entitled "Combination Immuno-Oncology Themes." HTBX: 1.34 (-0.02)
FDA Lifts Heat Biologics Partial Clinical Hold
GlobeNewswire - Wed Feb 10, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's Phase 2 clinical trial evaluating HS-410 either alone or in combination with standard of care Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer (NMIBC). Heat will resume patient enrollment. HTBX: 1.34 (-0.02)
HIV-1 Infection - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8h7d/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Beth Israel Deaconess Medical Center, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Chipscreen Biosciences Ltd - CompleGen, Inc. - Critical Outcome Technologies Inc. - Cytodyn Inc. - Dong-A ST Co., Ltd. - Enzo Biochem, Inc. - Evofem, Inc. - FIT Biotech Oy - Formune S.L. - Frontier Biotechnologies Co., Ltd - GeneCure LLC - Genetic Immunity, Inc - Gilead Sciences, Inc. - GlaxoSmithKline Plc - H-Phar S.A. - Heat Biologics, Inc. - (20 Others) For more information visit http://www.researchandmarkets.com/research/px..._infection
HTBX: 1.34 (-0.02), ARGS: 4.93 (-0.02), ENZ: 5.74 (-0.11), GILD: 77.59 (+0.17), GSK: 44.08 (+1.10), BMY: 55.94 (-0.82)
Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
GlobeNewswire - Tue Jan 26, 6:02AM CST
-- Early results support mechanism of action
HTBX: 1.34 (-0.02)
Heat Biologics to Present at Biotech Showcase 2016
GlobeNewswire - Thu Jan 07, 3:14PM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that Jeff Wolf, Heat's Chief Executive Officer, will deliver a corporate presentation at the 8 Annual Biotech Showcase(TM), being held January 11-13, 2016 in San Francisco, CA. HTBX: 1.34 (-0.02)
Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
M2 - Tue Dec 22, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/q3dfhj/global_cancer) has announced the addition of the "Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020" report to their offering. The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period. Key Topics Covered: 1. Executive Summary 2. Global - Cancer Vaccines Market and Forecast to 2020 3. Global - Cancer Vaccines Market Share and Forecast to 2020 4. Global - Prophylactic Cancer Vaccines Market and Forecast to 2020 5. Global - Therapeutics Cancer Vaccines Market and Forecast to 2020 6. Cancer Vaccines Market - Regional Analysis 7. Global Cancer Vaccines Market - Major Deals 8. Global Cancer Vaccines - Funding 9. Global Cancer Vaccines Market - Pipeline Portfolio Analysis 10. Company Cancer Vaccines - Pipeline Analysis 11. Global Cancer Vaccines Market - Driving Factors 12. Global Cancer Vaccines Market - Challenges Companies Mentioned: - Aduro Biotech - Advantagene - Advaxis - Agenus - AlphaVax - Altor BioScience - Argos Therapeutics - AVAX Technologies - Bavarian Nordic - Biothera - Celldex Therapeutics - CureVac - Galena Biopharma - Genexine - GlobeImmune - Gradalis - Heat Biologics - Immatics - ImmunoCellular Therapeutics - Inovio Pharmaceuticals - ISA Pharmaceuticals - Juvaris Biotherapeutics - NewLink Genetics - Northwest Biotherapeutics - NovaRx - OncoThyreon - Oncovir - Oxford BioMedica - Prima BioMed - Sotio - Transgene - Ubivac - Vaccinogen - Vaxon Biotech For more information visit http://www.researchandmarkets.com/research/q3...bal_cancer
HTBX: 1.34 (-0.02), INO: 9.18 (+0.04), ARGS: 4.93 (-0.02), NWBO: 0.34 (unch), ADRO: 14.15 (-0.07), CLDX: 3.33 (-0.03), NLNK: 10.39 (+0.08), GALE: 0.41 (+0.01), IMUC: 0.12 (-0.01)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015 - 15 Companies & 21 Drug Profiles
M2 - Mon Dec 07, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/s7bjp9/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - APIM Therapeutics AS - Astellas Pharma Inc. - Bavarian Nordic A/S - BioCancell Ltd - Celgene Corporation - Cold Genesys, Inc. - Heat Biologics, Inc. - Spectrum Pharmaceuticals, Inc. - TARIS BioMedical, Inc. - Telesta Therapeutics Inc. - Telormedix SA - Vakzine Projekt Management GmbH - Viralytics Ltd. - Viventia Biotechnologies Inc. Drug Profiles - ALT-801 - ALT-803 - apaziquone - APL-1202 - ATX-101 - BC-819 - Biologic for Superficial Bladder Cancer - CG-0070 - CV-301 - CVA-21 - DAB-389EGF - docetaxel - Drug for NMIBC - erlotinib hydrochloride - imiquimod - lenalidomide - mitomycin SR - Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - oportuzumab monatox - rAd-IFN - sirolimus albumin-bound - TD-210 - Urocidin - vesigenurtucel-L - VPM-1002 For more information visit http://www.researchandmarkets.com/research/s7bjp9/non_muscle
HTBX: 1.34 (-0.02), SPPI: 5.20 (-0.09), CELGZ: 1.13 (-0.03)
Heat Biologics Appoints Timothy Creech as Chief Financial Officer
GlobeNewswire - Tue Dec 01, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced the appointment of Timothy Creech as Heat's new Chief Financial Officer. HTBX: 1.34 (-0.02)
Heat Biologics Selected as One of Informa's 2015 Top 10 Immuno-Oncology Companies to Watch
GlobeNewswire - Wed Nov 18, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, has been chosen by Informa as one of the 2015 Top 10 Immuno-Oncology Companies to Watch. Anil Goyal, Ph.D., Heat's Vice President of Business Development, will present at the 10 Annual Therapeutic Area Partnerships meeting on November 18-20, 2015 at the Hilton Back Bay in Boston. Dr. Goyal's presentation is scheduled on Thursday, November 19, 2015 at 1:15 p.m. Eastern Time. HTBX: 1.34 (-0.02)
Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire - Fri Nov 06, 6:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced results from its Phase 1 trial to evaluate safety and immune response to HS-410 (vesigenurtacel-L), after standard of care Bacillus Calmette-Guerin (BCG), for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). HS-410 had a positive safety profile and was well-tolerated with no patients discontinuing the trial due to adverse events. Furthermore, no serious adverse events were reported, and 7 out of 10 patients had no documented recurrence of cancer >1 year after standard of care surgery. Significantly, 3 out of 4 patients with carcinoma in situ (CIS), the patient population least responsive to standard of care, did not recur. HTBX: 1.34 (-0.02)
